1.06
Cardiol Therapeutics Inc 주식(CRDL)의 최신 뉴스
Cardiol Therapeutics announces $13.5M bought-deal private placement - MSN
Cardiol Therapeutics announces $13.5 million private placement By Investing.com - Investing.com Nigeria
(CRDL) Technical Pivots with Risk Controls (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics announces $13.5 million bought deal financing By Investing.com - Investing.com Nigeria
Cardiol Therapeutics Inc. announced that it expects to receive CAD 13.500001 million in funding - marketscreener.com
Cardiol Therapeutics Secures $13.5 Million Bought Deal Financing to Advance Heart Disease Programs - TipRanks
Cardiol Therapeutics announces $13.5 million private placement - Investing.com
Cardiol Therapeutics announces $13.5 million bought deal financing - Investing.com
Heart drug developer Cardiol lines up $13.5M to fund trials and research - Stock Titan
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million - TMX Newsfile
AI Stocks: Is NeuroSense Therapeutics Ltd Equity Warrant forming a bullish divergenceJuly 2025 Fed Impact & AI Enhanced Trading Signals - baoquankhu1.vn
Cardiol Therapeutics (TSE:CRDL) Stock Price Up 1.5% – Still a Buy? - Defense World
Cardiol Therapeutics (TSE:CRDL) Stock Price Up 1.5%Still a Buy? - MarketBeat
(CRDL) On The My Stocks Page (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives $8.00 Consensus Price Target from Analysts - Defense World
Insider Sell: Is Cardiol Therapeutics Inc stock a safe investment in uncertain markets2025 EndofYear Setup & Consistent Return Strategy Ideas - Bộ Nội Vụ
Cardiol Therapeutics reaches 50% enrollment in recurrent pericarditis trial By Investing.com - Investing.com Nigeria
Stocks in play: Cardiol Therapeutics Inc. - Barchart.com
Cardiol Therapeutics Reaches 50% Enrollment in Pivotal Phase III MAVERIC Trial for Recurrent Pericarditis - TipRanks
Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Investing News Network
Heart inflammation trial reaches halfway mark in testing oral therapy - Stock Titan
Aug Movers: Can Cardiol Therapeutics Inc maintain its current growth rateJuly 2025 Weekly Recap & High Conviction Trade Alerts - baoquankhu1.vn
Analysts Expect Breakeven For Cardiol Therapeutics Inc. (TSE:CRDL) Before Long - Yahoo Finance
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
(CRDL) Stock Trading Blueprint (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics Reports Financial Challenges Amid Clinical Progress - MSN
What makes Cardiol Therapeutics Inc. stock attractive to growth fundsModel Comparison & lightweight options for faster days - Улправда
Why Cardiol Therapeutics Inc. stock could benefit from AI revolutionJuly 2025 WrapUp & Fast Gain Stock Trading Tips - Улправда
Is Cardiol Therapeutics Inc. stock trading near support levelsAnalyst Downgrade & Advanced Technical Analysis Signals - Улправда
Aug Selloffs: Why Cardiol Therapeutics Inc. stock could benefit from AI revolutionPortfolio Risk Summary & High Conviction Buy Zone Alerts - Улправда
Is Cardiol Therapeutics Inc. (CT9) stock suitable for passive index fundsEarnings Beat & Reliable Breakout Forecasts - ulpravda.ru
Is Cardiol Therapeutics Inc. stock a buy on dipsBond Market & Community Trade Idea Sharing - Улправда
Can Cardiol Therapeutics Inc. (CT9) stock retain market dominanceShort Setup & Stock Portfolio Risk Management - ulpravda.ru
How Cardiol Therapeutics Inc. stock reacts to job market dataBuy Signal & AI Driven Stock Reports - Улправда
How institutional buying supports Cardiol Therapeutics Inc. stockLayoff News & High Return Stock Watch Alerts - Улправда
Is Cardiol Therapeutics Inc. stock attractive for growth ETFs2025 Short Interest & Growth-Oriented Investment Plans - ulpravda.ru
How Cardiol Therapeutics Inc. stock performs in weak economyLong Setup & AI Enhanced Trading Signals - Улправда
(CRDL) Technical Analysis and Trading Signals (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics (NASDAQ:CRDL) Trading 1% HigherHere's What Happened - MarketBeat
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
(CRDL) Strategic Market Analysis (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics (OTCMKTS:CRTPF) Stock Price Down 1.7% – Should You Sell? - Defense World
Learn to Evaluate (CRDL) using the Charts (CRDL:CA) - Stock Traders Daily
Movement Recap: Why Cardiol Therapeutics Inc stock could benefit from AI revolutionWeekly Risk Report & Risk Adjusted Swing Trade Ideas - moha.gov.vn
Trading (CRDL) With Integrated Risk Controls (CRDL:CA) - Stock Traders Daily
Cardiol TherapeuticsFinancial Details - Crunchbase
HC Wainwright & Co. Reiterates Cardiol Therapeutics (CRDL) Buy Recommendation - MSN
(CRDL) Financial Trading Report (CRDL:CA) - Stock Traders Daily
Cardiol Therapeutics (TSE:CRDL) Stock Price Down 0.7%Here's Why - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Stock Price Down 0.7% – Here’s Why - Defense World
Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Target Price at $8.00 - Defense World
CapEx per share of Cardiol Therapeutics Inc. – NASDAQ:CRDL - TradingView — Track All Markets
EBITDA per share of Cardiol Therapeutics Inc. – NASDAQ:CRDL - TradingView — Track All Markets
Why Cardiol Therapeutics Inc. stock attracts global investorsJuly 2025 News Drivers & Momentum Based Trading Ideas - Улправда
Is Cardiol Therapeutics Inc. stock near bottom after declineJuly 2025 Update & Growth Focused Entry Reports - Улправда
Why Cardiol Therapeutics Inc. stock is favored by top institutions2025 Performance Recap & Capital Efficiency Focused Ideas - DonanımHaber
Is Cardiol Therapeutics Inc. (CT9) stock a momentum leaderMarket Sentiment Report & AI Enhanced Trading Alerts - Улправда
Moderna to Present at the 44th Annual J.P. Morgan Healthcare Conference - Investing News Network
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
자본화:
|
볼륨(24시간):